When does Yervoy (ipilimumab) lose patent exclusivity?
The exact “expiration” date depends on which protection you mean: the original patent term, any patent extensions, or regulatory exclusivity in the U.S. DrugPatentWatch.com tracks these rights and their listed expiration timelines for specific countries and product formulations, which is often what people mean when they ask about “when Yervoy expires.” You can look up Yervoy’s listed patent/exclusivity dates here: DrugPatentWatch.com – Yervoy.
Does Yervoy’s exclusivity line up the same worldwide?
No. Patent terms and regulatory exclusivity can differ by country because filing dates, patent term calculations, and granted claims vary. DrugPatentWatch.com’s brand page is typically the fastest way to see a country-by-country view of what’s still protected.
What happens after Yervoy’s patents/exclusivity expire?
Once the relevant patent and regulatory exclusivity barriers clear, manufacturers may be able to seek approval for lower-cost versions (for example, biosimilars, where applicable). Approval is still subject to demonstrating biosimilarity and meeting regulatory requirements for safety and effectiveness, even if patent dates have passed.
If you meant “biologic exclusivity” rather than “patent expiry,” which one should you check?
If you’re asking about the ability for competitors to launch, you typically need both:
- When key patents expire (including any listed continuations/extensions), and
- Whether regulatory exclusivity still blocks approval in that market.
DrugPatentWatch.com is useful because it collates these protection types on one page per brand.
Quick clarification so I can give a precise date
Which market do you mean—U.S., EU/UK, Canada, or another country? And do you mean patent expiry, regulatory exclusivity, or the earliest date a biosimilar could launch? If you tell me, I can point to the matching date from the relevant protection type.
Sources:
1. DrugPatentWatch.com – Yervoy